-

07:32:50 PM

ATHE Stock News

ATHE - Alterity Therapeutics Ltd

03/16/23 7:25 AM

Nasdaq : ATHE

clinical triallow float

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first

RHEA-AI

neutral

03/14/23 7:25 AM

Nasdaq : ATHE

low float

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed to Professor Colin Masters for evaluation in Alzheimer’s and related diseases – MELBOURNE, Australia

RHEA-AI

very positive

03/08/23 7:25 AM

Nasdaq : ATHE

clinical triallow float

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first

RHEA-AI

neutral

02/16/23 4:44 PM

Nasdaq : ATHE

clinical triallow float

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Company has

RHEA-AI

neutral

01/31/23 7:25 AM

Nasdaq : ATHE

low float

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia, the United States, and Italy Presented compelling bioMUSE data at two prestigious industry conferences Granted a 20- year patent for 100 new compounds targeting Parkinson's and Alzheimer's disease Cash balance on 31 December 2022 of A $25.3 M.

RHEA-AI

neutral

01/09/23 10:25 AM

Nasdaq : ATHE

clinical triallow float

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying

RHEA-AI

neutral

01/06/23 7:25 AM

Nasdaq : ATHE

low float

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of

RHEA-AI

neutral

01/03/23 10:25 AM

Nasdaq : ATHE

conferenceslow float

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D.,

RHEA-AI

neutral

12/29/22 10:25 AM

Nasdaq : ATHE

low float

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company

RHEA-AI

neutral

11/07/22 10:25 AM

Nasdaq : ATHE

low float

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from

RHEA-AI

very negative

1 2 3 4 5 6 Next